Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA'S Meacham
06:49pm, Monday, 26'th Jun 2023
Geoff Meacham, Bank of America Securities, joins 'Fast Money to discuss the state of the weight-loss drug market as Eli Lilly and Novo Nordisk compete for market share.
Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
06:24pm, Monday, 26'th Jun 2023
By 48 weeks, patients who took Eli Lilly's retatrutide lost 58 pounds on average, the pharmaceutical company said in a mid-stage clinical trial.
Lilly experimental 'triple g' obesity drug leads to 24.2% weight loss in trial -NEJM
05:43pm, Monday, 26'th Jun 2023
Eli Lilly's mid-stage trial of its next-generation "triple g" obesity drug candidate found that the highest dose of the weekly injection to led to weight loss of 24.2% after 48 weeks, the New England
Trial anticipation for weight loss drugs shows they will be popular, says Dr. Kavita Patel
03:30pm, Monday, 26'th Jun 2023
Dr. Kavita Patel, NBC News medical contributor, joins 'Power Lunch' to discuss the anticipation for weight loss drugs.
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
Experimental Lilly pill leads to 14.7% weight loss in mid-stage trial
05:34pm, Friday, 23'rd Jun 2023
Results from a mid-stage trial found that the highest dose of Eli Lilly's experimental pill orforglipron helped people who were obese or overweight lose 14.7% of their body weight after 36 weeks, the
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
02:06pm, Thursday, 22'nd Jun 2023
Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.
More News Is Coming on Lilly, Novo Nordisk's New Weight-Loss Drugs
03:30am, Thursday, 22'nd Jun 2023
At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.
FDA approves Eli Lilly and Boehringer Ingelheim's Jardiance for children 10 and older with type 2 diabetes
01:29pm, Wednesday, 21'st Jun 2023
The U.S. Food and Drug Administration has approved the use of Jardiance 10 mg and 25 mg tables to lower blood sugar along with diet and exercise in children aged 10 years and older with type 2 diabete
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
01:19pm, Wednesday, 21'st Jun 2023
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, s
Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker
11:35am, Wednesday, 21'st Jun 2023
Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
11:30am, Wednesday, 21'st Jun 2023
Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
09:35am, Wednesday, 21'st Jun 2023
On Tuesday, the nearly 150-year pharmaceutical giant announced an agreement to acquire San Francisco-based immunology specialist DICE Therapeutics. Under the terms of the deal, Lilly will pay $48.00 p
US FDA approves Eli Lilly-Boehringer's diabetes drugs for children
06:07pm, Tuesday, 20'th Jun 2023
The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
04:01pm, Tuesday, 20'th Jun 2023
Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.
